Version history

{
  "session_id": "sess_SDA-2026-04-08-gap-pubmed-20260406-062111-db808ee9",
  "round_number": 3,
  "agent_persona": "persona-domain_expert",
  "agent_backend": "us.anthropic.claude-sonnet-4-20250514-v1:0",
  "action": "support",
  "content": "## PRACTICAL FEASIBILITY RANKING\n\n### Tier 1 (Immediately Feasible - Repurposing Opportunity)\n1. **S1P Pathway (Hypothesis 7)**: Fingolimod/siponimod already approved, safety known, could be tested in myelopathy populations within 2-3 years\n2. **Complement System (Hypothesis 3)**: Avacopan approved for vasculitis, eculizumab proven safe, strong mechanistic rationale\n\n### Tier 2 (Feasible with Significant Investment)\n3. **JAK/STAT3 (Hypothesis 5)**: Need CNS-penetrant compounds, but pathway validated\n4. **VEGF/Barrier (Hypothesis 2)**: Only if pursuing barrier-protective rather than inhibitory approach\n\n### Tier 3 (High Risk/Poor Feasibility)\n5. **Microglia (Hypothesis 1)**: Safety concerns, previous failures\n6. **Ferroptosis (Hypothesis 6)**: Druggability challenges\n7. **ER Stress (Hypothesis 4)**: Unacceptable safety profile\n\n## INVESTMENT RECOMMENDATIONS\n\n**Immediate Action (6-12 months):**\n- **S1P Repurposing Study**: $2-5M investigator-initiated trial of fingolimod in acute myelitis\n- **Complement Biomarker Study**: $1-3M to validate C5a levels across myelopathy etiologies\n\n**Medium-term Investment (2-5 years):**\n- **CNS-penetrant JAK inhibitors**: $50-100M medicinal chemistry program\n- **Complement pathway expansion**: $20-50M to test avacopan in broader myelopathy indications\n\n**Avoid:**\n- Any PERK/ER stress modulators (safety)\n- Broad microglial inhibition (mechanism concerns)\n\n**Reality Check:** The most pragmatic approach is repurposing existing drugs (fingolimod, avacopan) for proof-of-concept studies before committing to novel drug development. The convergent pathway hypothesis remains unproven and needs validation before major investment.",
  "tokens_used": "419",
  "persona_id": "persona-domain_expert"
}